WordNet

a medicine that lowers blood cholesterol levels by inhibiting HMG-CoA reductase (同)lipid-lowering medication, statin drug, statin
(medicine) something that treats or prevents or alleviates the symptoms of disease (同)medication, medicament, medicinal drug
the learned profession that is mastered by graduate training in a medical school and that is devoted to preventing or alleviating or curing diseases and injuries; "he studied medicine at Harvard" (同)practice of medicine
the branches of medical science that deal with nonsurgical techniques (同)medical_specialty
(botany) either of the two parts of a bilabiate corolla or calyx
either the outer margin or the inner margin of the aperture of a gastropods shell
either of two fleshy folds of tissue that surround the mouth and play a role in speaking
the act of causing something to move to a lower level (同)letting down
the act of causing to become less
an oily organic compound insoluble in water but soluble in organic solvents; essential structural component of living cells (along with proteins and carbohydrates) (同)lipide, lipoid

PrepTutorEJDIC

〈U〉『医学』,医術;医[師]業 / 〈C〉〈U〉(外用薬以外の)『薬』[『剤』],内服薬 / 〈U〉(北米インディアンの間で行われる)病気(悪霊)を追い払うまじない
〈C〉『くちびる』,口もと / 《複数形で》(発音器官としての)くちびる,口 / 〈U〉《俗》生意気な言葉 / 〈C〉(容器などの)口,へり,縁;(峡谷・火山などの)口 / 〈C〉(植物の)唇弁(しんべん)
低くする,低下させる;堕落させる
(空模様が)険悪な,荒れ模様の / しかめっつらの,(顔つきが)不機嫌な
脂質,あぶら

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 心血管疾患または糖尿病患者におけるコレステロール低下に関する臨床試験 clinical trials of cholesterol lowering in patients with cardiovascular disease or diabetes
2. 冠動脈疾患患者における脂質低下薬の利益の機序 mechanisms of benefit of lipid lowering drugs in patients with coronary heart disease
3. 食事または栄養補助食品による脂質低下 lipid lowering with diet or dietary supplements
4. オーダーメイド医療 personalized medicine
5. 急性冠症候群後の低比重リポ蛋白コレステロール（LDL)低下 low density lipoprotein cholesterol ldl c lowering after an acute coronary syndrome

English Journal

Effect of dietary supplementation of black seed (N. Sativa L.) on lipid profile of patients suffering from diabetes.

Qidwai W, Ashfaq T.Author information Department of Family Medicine, Aga Khan University, Stadium Road, P.O. Box: 3500, Karachi 74800, Pakistan. tabinda.ashfaq@aku.edu.AbstractDiabetes is a chronic metabolic problem closely related to cardiovascular disease leading to premature death. Dyslipidemia is an important risk factor responsible for cardiovascular disease in patients with diabetes. This paper is based on review of articles published to observe the effect of N. Sativa (black seed) on lipid levels in patients suffering from Diabetes Mellitus. A search of indexed papers and clinical trials was done using MEDLINE and PubMed and Cochrane search engine. All studies assessing the effect of N. Sativa ingestion on lipid levels among diabetics (animal or human) were included. A total of 12 trials (6 human studies and 6 animal studies) fulfilling the inclusion criteria were reviewed. Majority of human and animal trials done among humans and animals with diabetes or metabolic syndrome demonstrated reduction in weight and improvement in serum lipid levels including decrease total lipids, triglycerides, LDL levels. However, increase in HDL level showed questionable results. N. Sativa L and its different preparations can be used as an adjuvant with lipid lowering drugs for control of lipids however its role as a main therapeutic agent cannot be recommended and more metanalysis using standardized preparations with a close watch on methodological short falls is suggested to prove its role.
Anti-inflammatory & anti-allergy agents in medicinal chemistry.Antiinflamm Antiallergy Agents Med Chem.2014 Mar;13(1):3-8.
Diabetes is a chronic metabolic problem closely related to cardiovascular disease leading to premature death. Dyslipidemia is an important risk factor responsible for cardiovascular disease in patients with diabetes. This paper is based on review of articles published to observe the effect of N. Sat
PMID 24484208

Statin treatment, new-onset diabetes, and other adverse effects: a systematic review.

Bang CN, Okin PM.Author information Department of Medicine, Division of Cardiology, Weill Cornell Medical College, New York, NY, USA, casperbang@hotmail.com.AbstractStatin treatment prevents cardiovascular diseases probably beyond their lipid-lowering effect. Increasing evidence suggests that statins might increase the risk of new-onset diabetes; however, diabetes is known to increase the risk of cardiovascular diseases. The majority of the literature suggests an increased risk of new-onset diabetes in patients treated with statins in a number of different settings and that the risk appears greatest among the more potent statins. Furthermore, a dose-response curve has been shown between statin treatment and the development of diabetes. Possible mechanisms include muscle insulin resistance, lower expression of GLUT-4 in adipocytes impairing glucose tolerance and suppression of glucose-induced elevation of intracellular Ca(2+) level. However, other side effects have been reported such as increased risk of myotoxicity, increased liver enzymes, cataracts, mood disorders, dementias, hemorrhagic stroke and peripheral neuropathy, which should maybe be added to the increased risk of new-onset diabetes, when considering the risk- benefit ratio of statin treatment.
Current cardiology reports.Curr Cardiol Rep.2014 Mar;16(3):461. doi: 10.1007/s11886-013-0461-4.
Statin treatment prevents cardiovascular diseases probably beyond their lipid-lowering effect. Increasing evidence suggests that statins might increase the risk of new-onset diabetes; however, diabetes is known to increase the risk of cardiovascular diseases. The majority of the literature suggests
PMID 24464306

Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe.

Habara M1, Nasu K2, Terashima M1, Ko E1, Yokota D1, Ito T1, Kurita T1, Teramoto T1, Kimura M1, Kinoshita Y1, Tsuchikane E1, Asakura Y1, Matsubara T1, Suzuki T1.Author information 1Department of Cardiovascular Medicine, Toyohashi Heart Center, Toyohashi, Japan.2Department of Cardiovascular Medicine, Toyohashi Heart Center, Toyohashi, Japan. Electronic address: yuyatomoya@gmail.com.AbstractAlthough lipid-lowering therapy with statin and ezetimibe has been reported to provide greater reduction in low-density lipoprotein cholesterol levels than statin monotherapy, the effect of supplemental therapy on plaque stabilization is yet to be fully elucidated. Cap thickness of fibroatheroma evaluated by optical coherence tomography (OCT) is a major determinant of vulnerable plaque. The primary objective of this study is to evaluate the effect of ezetimibe in addition to fluvastatin on the progression of coronary atherosclerotic plaque evaluated by OCT. Sixty-three patients with angina pectoris with intermediate, nonculprit, lipid-rich plaque lesions evaluated by OCT were enrolled. The patients were divided into 2 groups: ezetimibe (10 mg/day) + fluvastatin (30 mg/day), and fluvastatin (30 mg/day) alone, and serial OCT examinations were performed at baseline and 9-month follow-up. A total of 57 patients (ezetimibe + fluvastatin, n = 31; fluvastatin alone, n = 26) underwent serial OCT examinations. The change in low-density lipoprotein cholesterol level was significantly larger in the ezetimibe + fluvastatin group compared with fluvastatin-alone group (-34.0 ± 32.0 vs -8.3 ± 17.4 mg/dl, p <0.001). Fibrous cap thickness was significantly increased and the angle of the lipid plaque was significantly decreased in both groups. The change in the fibrous cap thickness was significantly greater in the ezetimibe + fluvastatin group (0.08 ± 0.08 mm vs 0.04 ± 0.06 mm, p <0.001). In conclusion, lipid-lowering therapy by ezetimibe + fluvastatin could increase the fibrous cap thickness of lipid-rich plaque compared with fluvastatin monotherapy.
The American journal of cardiology.Am J Cardiol.2014 Feb 15;113(4):580-7. doi: 10.1016/j.amjcard.2013.10.038. Epub 2013 Nov 22.
Although lipid-lowering therapy with statin and ezetimibe has been reported to provide greater reduction in low-density lipoprotein cholesterol levels than statin monotherapy, the effect of supplemental therapy on plaque stabilization is yet to be fully elucidated. Cap thickness of fibroatheroma ev
PMID 24388622

Japanese Journal

Effect of Intensive Lipid-Lowering Therapy With Rosuvastatin on Progression of Carotid Intima-Media Thickness in Japanese Patients : Justification for Atherosclerosis Regression Treatment (JART) Study

NOHARA Ryuji,DAIDA Hiroyuki,HATA Mitsumasa,KAKU Kohei,KAWAMORI Ryuzo,KISHIMOTO Junji,KURABAYASHI Masahiko,MASUDA Izuru,SAKUMA Ichiro,YAMAZAKI Tsutomu,YOKOI Hiroyoshi,YOSHIDA Wasayuki
Circulation journal : official journal of the Japanese Circulation Society 76(1), 221-229, 2011-12-25
NAID 10030034830

Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration : HEAVEN Study

KOVARNIK Tomas,MINTZ Gary S.,SKALICKA Hana,KRAL Ales,HORAK Jan,SKULEC Roman,UHROVA Jana,MARTASEK Pavel,DOWNE Richard W.,WAHLE Andreas,SONKA Milan,MRAZEK Vratislav,ASCHERMANN Michael,LINHART Ales
Circulation journal : official journal of the Japanese Circulation Society 76(1), 176-183, 2011-12-25
… biBackground:/i/b There is no study focusing on changes in coronary atherosclerosis during dual lipid-lowering therapy with statin and ezetimibe. … biConclusions:/i/b Dual lipid-lowering therapy starts atherosclerosis regression, but does not lead to significant changes in plaque composition. …
NAID 10030034614

Low-Dose Rosuvastatin Improves Arterial Stiffness in High-Risk Japanese Patients With Dyslipdemia in a Primary Prevention Group : A Comparison With Fluvastatin

HONGO Minoru,KUMAZAKI Setsuo,IZAWA Atsushi,HIDAKA Hiroya,TOMITA Takeshi,YAZAKI Yoshikazu,KINOSHITA Osamu,IKEDA Uichi
Circulation journal : official journal of the Japanese Circulation Society 75(11), 2660-2667, 2011-10-25
… The results suggest that improvement in arterial stiffness by rosuvastatin mainly depends on its strong lipid-lowering effects, whereas that by fluvastatin is strongly dependent on the pleiotropic effects, especially an anti-inflammatory action. …
NAID 10030032449